TruSight Oncology 500 Comprehensive Assay​

TruSight Oncology 500 Comprehensive Assay​

Non-invasive detection of immunotherapy biomarkers

Pan-Cancer Comprehensive Genomic Profiling of Solid Tumors​

Gain an expansive view of your solid tumor samples by targeting 523 cancer-related genes using the TruSight Oncology 500 comprehensive assay. Not only does this assay identify all relevant variants (SNVs, insertions, deletions, CNVs, gene fusions, and transcript variants) across various tumor types, but it also reports tumor mutational burden (TMB) score and microsatellite instability (MSI) status.

 

Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. Q2 can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.

tso500comprehensive

An Efficient, Reliable Solution for Tumor Characterization

minimal-sample-blue
Minimal input, extensive results

Obtain full exon coverage of 522 genes using as little as 40ng of FFPE DNA and RNA input.

measure-dna-blue
Measurement of key immuno-oncology biomarkers

Gain insight into TMB score and MSI status in addition to variant calls. TruSight Oncology 500 can reproducibly assess TMB and reliably determine TMB-H, making it a competitive offering for TMB assessment*.

precision
Confident variant detection

Obtain a high-resolution view of variants enabled by TSO500’s hybrid-capture chemistry and unique molecular indices.

workflow-savings-blue
Simple, cost-effective workflow

Detect multiple biomarkers with a single assay to save time, money, and samples.

global-network-blue
Extensive services enabled by our global network

Our centralized scientific operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.

flexible-filter-blue
Flexible customization to satisfy specific needs

We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.


Comprehensive Panel Content​

The TruSight Oncology 500 Comprehensive assay can detect …. To view the full gene list, please refer to the TruSight Oncology Panel Content document.

1.94

Mb of DNA

 

358

kb of RNA

 

1.94

Microsatellite Instability Sites​

 

523

Tumor Mutational Burden Genes

 

3

RNA Splice Variant Genes

 

523

Small Variants (SNVs & Indels) Genes

 

59

Copy Number Variant Genes​

 

55

RNA Fusions Genes

 

Assay Comparison

sect5-circles_v2b

 

Request a Quote

Supporting Studies Around the World

Our centralized, scientific, and operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. You will be supported every step of the way by our scientific project management team who will work with you to understand the most cost-effective recommendations to meet your specific needs. We are committed to transparency so you can feel confident in our promises of quality and timely delivery. We can expert support team can meet your research needs from nearly anywhere in the world with our genomic centers in the United States, China, United Kingdom, and Singapore.

 

global-delivery-network-map

Simplify Your Work

 

8-2-3-4

Request a Quote

Request a quote today to discovery how TSO500 with Q2 can advance your research.

Ship Samples​

Ship your samples to one of our global genomic laboratory centers.​

Get Results

Obtain in-depth data revealing insights into your solid tumor samples.

Request a Quote

Related Thought Leaders Insights


TruSight Oncology 500 (TSO500) Comprehensive Assay

The TruSight Oncology 500 (TSO500) comprehensive assay employs a hybrid capture-based approach targeting 523 clinically relevant genes and leverages unique molecular indices to enable low frequency...

Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay

Checkpoint inhibitor (CPI) therapy demonstrates a remarkable clinical benefit in many cancer types. However, the ability to successfully select patients who will benefit from CPIs is still limited....

TMB Standardization by Alignment to Reference Standards

At ASCO 2019, we presented a poster with Friends of Cancer Research (FOCR), highlighting their Tumor Mutational Burden (TMB) Harmonization Project. The goal of this Project is to harmonize TMB...